In summary, sFRP4 chemo-sensitizes CSCs derived from breast, prostate, and ovary tumor cell lines by reducing their pro-oncogenic profile, stemness capacity, cell survival protein and oncogene expression, making them more responsive to chemotherapeutic drugs. Here, SFRP4 is linked to ovarian neoplasm.